|
In silico
effective inhibition of galtifloxacin on built Mtb-DNA gyrase
D. Gowsia, B. Babajan, M. Chaitanya, C. Rajasekhar , P. Madhusudana, C. M. Anuradha
, G. Ramakrishna, K. R. S. Sambasiva
Rao and Chitta Suresh Kumar
1DBT-Bioiformatics Facility Center, Department of Biochemistry, S.K.
University, Anantapur-515055.
2Department of Biotechnology, Acharya Nagarjuna University, Guntur, India.
3 Department of Microbiology, Govt. College (for Boys), Anantapur-515055.
*Corresponding author. E-mail:
chitta34c@gmail.com.
Tel:+91-8554-255644.
Fax: +91-855-255805.
Accepted 10 October, 2009
|
|
Tuberculosis (TB) resurged in the late 1980s and now kills
approximately 3 million people a year. The reemergence of
tuberculosis as a public health threat has created a need to
develop new anti-mycobacterial agents. The Mtb-DNA Gyrase is
an attractive target for development of new drugs due to its
indispensable role in catalyzing the negative supercoiling
of DNA and is essential for efficient DNA replication,
transcription and recombination. Fluoroquinolone families of
inhibitors are developed against the Mtb-DNA gyrase which
show the best inhibition with DNA gyrase in the past. Due to
the development of Multi-drug resistant Mycobacterium
tuberculosis strains, the drugs showed less efficiency on
the targets, recently, a new flouroquinolone inhibitor was
identified (Galtifloxacin), which shown best inhibition. In
this study we carried out Homology model of 0 Mtb-DNA
gyrase, secondary structure analysis and active site
analysis. Docking studies were also carried out with the
Galtifloxacin and Amifloxacin and are helpful for further
studies on the development of novel drugs against Mtb-DNA
gyrase.
Key
words: Mycobacterium tuberculosis, DNA gyrase,
Galtifloxacin, Amifloxacin, Homology modeling, docking. |
